Podcasts about neuro oncology

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.In this special edition of Mind Moments, Na Tosha Gatson, MD, PhD, senior medical director of neuro-oncology and director of the Center for Neuro-Oncology at Indiana University School of Medicine, joins the podcast to discuss her career journey, philosophy of patient care, and the launch of The G.L.O.B., a new recurring NeurologyLive column dedicated to advancing health literacy in neuro-oncology. Drawing on decades of experience in neuro-oncology, clinical leadership, and mentorship, Gatson shares the motivation behind creating a platform that transforms complex oncologic concepts into practical, accessible knowledge for clinicians, patients, and caregivers alike. The conversation explores the inspiration behind The G.L.O.B., the importance of effective medical communication, lessons learned throughout Gatson's career, and the role of health literacy, shared decision-making, and health equity in modern neurologic care. She also discusses her vision for the future of the column and why improving patient understanding should remain central to both clinical practice and research. Episode Breakdown: 1:10 – Journey into neuro-oncology and career-defining experiences 4:50 – Mission and philosophy behind The G.L.O.B. 7:10 – Key themes readers can expect from the column 9:45 – Career lessons that shaped Dr. Gatson's clinical practice 16:30 – Vision for The G.L.O.B. and improving healthy literacy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Podcast Host and Interviewee: Shahad Abdulsahib, PhD Graduate, UT Health San Antonio Podcast Description: Shahad Abdulsahib discusses a landmark preclinical study evaluating Synthetic Super-Enhancer-based gene therapy for glioblastoma, published in Nature in April 2026, and the rapid translation of these findings into the first-in-human Phase 1/2 ADePT clinical trial with first patient dosing in May 2026.

Podcast Host and Interviewee:  Host (Ashley Aaroe, MD) | Guests (Akanksha Sharma, MD, Soma Sengupta, MD, PhD, MBA) Podcast Description: This episode discusses what it means to practice integrative medicine in a neuro-oncology clinic, joined by guests Akanksha Sharma, MD (Sutter Health) and Soma Sengupta, MD, PhD, MBA (Tufts) - two neuro-oncologists whose work sits at the intersection of tumor-directed therapy, supportive care, and quality of life.  We discuss where integrative approaches fit alongside standard treatment, what the evidence does or does not support, and best practices for counseling patients and family members about complementary or alternative approaches. Links: https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs https://toolkit.awcim.arizona.edu/cancertoolkit/index.html  

Host/Interviewee: ç, PhD Candidate, UT Health San Antonio Description: Shahad Abdulsahib discusses the GT-20 phase 1 clinical trial evaluating GNOS-PV01, a personalized multivalent neoantigen DNA vaccine administered following surgical resection and radiation in patients with MGMT unmethylated glioblastoma, with findings published in Nature Cancer on May 12th, 2026.

Podcast Host and Interviewee: Rachna Malani, Sarah Menacho, Ben Shofty Rachna Malani interviews Drs. Menacho and Shofty, two Neurosurgeons who share their experiences in interfacing with Neurosurgery as well as their experiences as Neurosurgeons.

Podcast Host and Interviewee: Venina Kalistratova (host), Nick Gonzalez Castro and Raj Mukherjee (Interviewees) Podcast Description: The Co-chairs of the SNO Wellness Committee discuss wellness and ways to reduce burnout.

Host/Interviewee: Shahad Abdulsahib, PhD Graduate, UT Health San Antonio Description: Shahad Abdulsahib discusses the phase 1/2 BT008NA clinical trial evaluating microbubble-enhanced transcranial focused ultrasound combined with temozolomide in patients with newly diagnosed high-grade glioma, with findings published in The Lancet Oncology in December 2025

Podcast Host and Interviewee: Host: Dr. Dave Rogawski Interviewee: Dr. Fabio Iwamoto Dr. Dave Rogawski interviews Dr. Fabio Iwamoto, incoming Neuro-Oncology Division Chief at Stanford, about where we're headed in neuro-oncology.  

Podcast Host and Interviewee: Evan Noch, Producer, Neuro-oncology: The Podcast Podcast Description: Evan Noch discusses recent career development outreach from SNO

Dr. Dave Rogawski interviews Dr. Mary Jane (MJ) Lim-Fat and Dr. Kee Kiat (Aaron) Yeo on patient care and research for the adolescent and young adult (AYA) population in neuro-oncology.

Shahad Abdulsahib discusses a phase 1 clinical trial of intracerebroventricular bivalent EGFR and IL13Rα2 CAR T cells for recurrent glioblastoma, published in Nature Medicine.

Send us Fan MailPaper Discussed in this Episode: Digital Twins in Neuro-Oncology: A Systematic Review of Current Implementations, Technical Strategies, and Clinical Applications. Annie Singh, Fatima Ahmad Qureshy, Angelica Kurtz, Moinak Bhattacharya, Prateek Prasanna, and Gagandeep Singh. Radiology: Imaging Cancer 2026; 8(2).Episode Summary: In this journal club deep dive, we explore a groundbreaking 2026 systematic review of digital twins in neuro-oncology. We step past the buzzwords and examine how exact virtual copies of patient brains are being built to safely simulate dangerous radiation regimens and drug combinations for highly aggressive tumors. This forces us to ask an uncomfortable question: Are we just slapping the label "digital twin" on static algorithms, or are we actually building living, continuously updating virtual copies of patient tumors? Furthermore, what happens to clinical ethics when a perfect simulation predicts a patient's tumor will resist every standard line of therapy before they even try it?In This Episode, We Cover:• Defining the True Twin: We break down what separates a standard, static computational model from a true digital twin. A real digital twin requires closed-loop optimization with continuous, real-time feedback from a patient's actual biological response—a critical feature shockingly missing in 13 out of the 21 reviewed models.• The Dominance of Old-School Math: Why the most advanced simulations aren't relying solely on modern machine learning, but rather mechanistic models built on reaction-diffusion differential equations. We explain how these models calculate variables like tumor cell density, proliferation rate, and tissue carrying capacity to simulate literal physical pressure in the brain. Transparency and trust trump "black box" AI when neuro-oncologists are making life-altering surgical decisions.• The AI Visual Forecaster: How cutting-edge AI diffusion models, like BrainMRDiff and ImmunoDiff, serve as hybrid partners to these math equations. These tools take complex biological calculations and generate high-fidelity, anatomically consistent visual MRIs to accurately forecast how a tumor will morph post-treatment.• Grading Their Own Homework: A look at the PROBAST risk of bias assessment, which revealed that while outcome accuracy seems high, many models suffer from overfitting, data leakage, and a massive lack of external validation.• The Big Bottlenecks - Broken Pipes and Locked Safes: We discuss the roadblocks keeping this out of the bedside. Specifically, the glaring lack of open-source code (only 6 of 21 studies shared theirs) makes standardization impossible. We also examine the engineering nightmare of multimodal data fusion—combining asynchronous streams of MRIs, genomics, and tissue pathology into a real-time model.Key Takeaway: While digital twins represent a monumental leap toward true precision medicine, the field is currently bottlenecked by proprietary secrecy and broken data infrastructure. Until the scientific community embraces open-source code sharing and hospital systems solve the complex engineering challenge of real-time multimodal data integration, these revolutionary tools will remain isolated research projects rather than the living clinical tools they are meant to beSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Shahad Abdulsahib discusses a phase 1 clinical trial of intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma, published in Nature Medicine in January 2025.

Dr. Sara Hardy interviews Drs. Ashlee Loughan and Sarah Brahn to talk about their groundbreaking work to improve quality of life for patients with brain tumors.

 Dr. Dave Rogawski interviews Dr. Akanksha Sharma on how we can optimize the meaningful, longitudinal relationships that drew many of us to the field.

Podcast Host and Interviewee: Shahad Abdulsahib, PhD Candidate, UT Health San Antonio Podcast Description: Shahad Abdulsahib discusses a recent Phase 1 clinical trial on Rhenium-186 nanoliposome therapy for recurrent glioma, published in Nature Communications in March 2025.

See the evidence linking long-term cell phone use to glioblastoma and heart irregularities, especially in youth. Are our devices silently harming us? #CellPhoneRadiation #BrainHealth #EMFExposure

Dr. Maya Graham interviews Dr. Lauren Schaff on her manuscript entitled "Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine (R-MVP/i) for newly diagnosed primary CNS lymphoma (PCNSL)," published in Neuro-Oncology in January 2026.

Shahad Abdulsahib discusses the findings of a recent paper, entitled "Transcriptional regulation of protein synthesis by mediator kinase represents a therapeutic vulnerability in MYC-driven medulloblastoma", which was published in Nature Communications in December 2025.

Dr. Jasmin Jo interviews Dr. Amy Smith and Dr. David Ellison on their manuscript, entitled "Phase 3 randomized trial of post-irradiation chemotherapy in patients with newly diagnosed ependymoma, a report from the Children's Oncology Group" published in Neuro-Oncology in December 2025.

Dr. Haseeb Mehmood discusses the use of microbubble-enhanced transcranial focused ultrasound combined with standard temozolomide in high-grade glioma.

Dr. Iyad Alnahhas interviews Drs. David Schiff and Ranjit Bindra about their recent manuscript entitled "Phase I/II and Window-of-Opportunity Study of Pamiparib and Metronomic Temozolomide for Recurrent IDH Mutant Gliomas", published online in Neuro-Oncology in October 2025.

In this episode, Dr. Evan Noch and Dr. Maya Graham discuss the exciting new podcast subtypes and the episodes to come.

Do you know how to implement novel targeted therapies into the glioma treatment algorithm? Join us to find out more!   Credit available for this activity expires: 1/6/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003198?ecd=bdc_podcast_libsyn_mscpedu

Do you know how to integrate IDH inhibitors into the glioma treatment algorithm? Join our expert panel as they discuss complex real-world cases and more! Credit available for this activity expires: 12/19/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003175?ecd=bdc_podcast_libsyn_mscpedu

Host Dr. Linda Chu speaks with Dr. Jana Ivanidze and Dr. Rajiv Magge about how molecular imaging is transforming the diagnosis and management of breast cancer brain metastases, with an emphasis on precision and personalized care. Their discussion highlights emerging tools such as advanced PET techniques and liquid biopsy that support earlier detection, guide treatment planning, and shape the future of neuro-oncology. Sponsored by GE HealthCare.      

Welcome to OncLive On Air®! OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today's episode, we had the pleasure of speaking with Cassie Kline, MD, MAS, about updated efficacy data from the phase 2 FIREFLY-1 study (NCT04775485) of tovorafenib (Ojemda) in patients with relapsed/refractory pediatric low-grade glioma (pLGG) that were presented at the 2025 Society of Neuro-Oncology Annual Meeting. Dr Kline is an attending physician and director of Clinical Research in the Department of Neuro-Oncology at Children's Hospital of Philadelphia in Pennsylvania. In our exclusive interview, Dr Kline discussed longer-term efficacy and safety data from the trial, noting the sustained response rates, continued tumor shrinkage, and rates of patients who remained treatment free after approximately 36 months of follow-up. _____ That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters. OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn. If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us! Thanks again for listening to OncLive On Air. *OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn. This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

Description: Dr. Iyad Alnahhas interviews Dr. Charlotte Sleurs about her and her team's recent manuscript entitled: "Radiotherapy-induced neurocognitive decline among adult intracranial tumor patients: A voxel-based approach", published online in Neuro-Oncology in May 2025.

Dr. Iyad Alnahhas interviews Drs. Florien Boele and Martin Klein about their recent manuscript entitled: “Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation”, published online in Neuro-Oncology in July 2025.

Dr. Iyad Alnahhas interviews Drs. Felix Sahm and Maximilian Deng about their recent manuscript entitled: "Postoperative radiotherapy in subtotally-resected recurrent WHO grade 1 meningiomas with intermediate/ high-risk molecular profiles", published online in Neuro-Oncology in May 2025.

In today's episode, supported by Chimerix, we spoke with Patrick Y. Wen, MD, about the FDA approval of dordaviprone (Modeyso) for the treatment of adult and pediatric patients at least 1 year of age with H3K27M-mutated diffuse midline glioma who have progressive disease following prior therapy. Dr Wen is the director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute; as well as a professor of neurology at Harvard Medical School in Boston, Massachusetts. In our conversation, Dr Wen discussed the significance of this accelerated approval across patient age groups, key efficacy and safety data that supported this approval, and the importance of biomarker testing in patients with glioma. He also highlighted potential next steps for expanding the investigation of dordaviprone in patients with glioma and emphasized the ways that multidisciplinary collaboration can provide patients with personalized, optimized care. 

Dr. Maya Graham interviews Dr. Jessica Foster about her and her team's recent manuscript, entitled "Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models". This work was published online in Neuro-Oncology in May 2025.

Welcome to another powerful episode of the Game Over: c*ncer podcast by Cannonball Kids' cancer Foundation (CKc)!In this conversation, hosts Dana and Val sit down with Dr. Cassie Kline, attending physician and Director of Clinical Research in the Department of Neuro-Oncology at Children's Hospital of Philadelphia.Dr. Kline shares her journey into pediatric oncology, her personal connection to cancer research, and her role in advancing innovative treatments for children with brain and spinal cord tumors. From her early days as CKc's first Young Investigator to serving on CKc's Scientific Advisory Board, Dr. Kline's story highlights the critical impact of research funding, mentorship, and collaboration in creating real hope for families.You'll hear insights on:The challenges young investigators face and why early funding is crucialHow clinical trials and immunotherapy are changing the future of pediatric brain tumor careThe role of CKc's Scientific Advisory Board in ensuring the most innovative research is fundedDr. Kline's perspective as a woman in STEM and the importance of diversity in medicineThis episode is a must-listen for anyone passionate about pediatric cancer research, advocacy, and the fight to deliver better treatment options for kids.Tune in to hear this inspiring and informative conversation. Don't forget to subscribe, leave a review, and join the fight to make Game Over: c*ncer a reality.Connect with our Guest Dr. Cassie Kline:  https://www.chop.edu/doctors/kline-cassieConnect with Dana: https://www.linkedin.com/in/danaknichols/Connect with Val: https://www.linkedin.com/in/valerie-solomon/Upcoming Ckc Events: https://cannonballkidscancer.org/category/make-an-impact/events/----------------------------------Podcast Produced by Hi Hello Labs: Website: https://www.hihellolabs.com/

Neuro-Oncology: Breakthroughs & Treatment Strategy with guest Dr. Sylvia Kurz July 20, 2025 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Neuro-Oncology: Breakthroughs & Treatment Strategy with guest Dr. Sylvia Kurz July 20, 2025 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Dr. Evan Noch interviews Dr. Akshitkumar Mistry about his and his team's recent manuscript entitled "A clinically annotated transcriptomic atlas of nervous system tumors", published online in Neuro-Oncology in May 2025 Link to the paper: https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaf130/8151442

Do you know anyone with dementia? If you don't, you will. We humans are living longer and healthier lives. There are more healthy 75 year old people alive now than there ever have been. However, the number of people with dementia is sky rocketing as well. Enter Dr. Mechtler…Dr. Lazslo Mechtler is the Medical Director of Dent Neurologic Institute, the Chief of Neuro-Oncology at Roswell Park Cancer Institute and is also the Director of the DENT Headache Center, Neuro-Oncology Center, and Cannabis Clinic.Dr. Mechtler gives us a fantastic review of dementia, and Alzheimer's disease. Then he talks about the work they are doing at the DENT Institute to treat dementia with cannabinoids.DENT Neurologic Institute - Cannabis Clinic - WebsiteLazlo Mechtler - LinkedInLazlo Mechtler - DENT-website profileMusic by:Christopher Cros - Sailing -YouTubeAdditional Music:Desiree Dorion desireedorion.comMarc Clement - FacebookTranscripts, papers and so much more at: reefermed.ca

Dr. Iyad Alnahhas interviews Drs. Isaias Hernandez-Verdin and Agusti Alentorn about their recent manuscript entitled: "Gut microbiome modulates the outcome in primary central nervous system lymphoma patients undergoing chemotherapy: An ancillary study from the BLOCAGE trial", published online in Neuro-Oncology in March 2025   Link: https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaf059/8058778

Dr. Evan Noch interviews Dr. Marion Mateos about her and her team's recent manuscript entitled: "Germline analysis of an international cohort of pediatric diffuse midline glioma patients", published online in Neuro-Oncology in March 2025.

Send us a textIn this episode, we sit down with Trishla to explore the world of neuro-oncology research. Trishla shares how meaningful moments shaped her passion for clinical trials and patient care. We discuss the challenges around access, the need for more research in brain cancer, and the options available to patients and families. Support the showRare Enough is a podcast powered by Head for the Cure, sharing real stories of resilience, hope, and community from those facing brain tumors and the people who walk beside them. Subscribe, listen, and share, because every story matters, and no one should face brain cancer alone. Follow on Instagram @RareEnoughPodcast Learn more at BrainsfortheCure.org

Dr. Iyad Alnahhas interviews Drs. Cynthia Hawkins and Arun Vadivel about their recent manuscript entitled: "The proteomic landscape of diffuse midline glioma highlights the therapeutic potential of non-histone protein methyltransferases", published online in Neuro-Oncology in February 2025.   More Information

Compassion and creativity are vitally important these days in cancer care. The old rule of thumb, especially in brain cancer, of standard of care just isn't enough anymore. Patients and families need a voice, and need to know that they are heard when asking questions about clinical trials, supplements, holistic options, and cross-collaboration across neuro-oncology care. Enter Dr.'s Soma Sengupta and Dominique Higgins of UNC School of Medicine in North Carolina. On today's episode (in total the 49th episode for Game On Glio), kicking off brain cancer awareness month, I sit down with them to discuss the crucial need for elevating patient voices, the importance of clinical trials like IGV-001, out of the box treatments (like GammaTile), and the novel way the doctors at UNC are helping patients reach new heights in their care.   Listen now or watch the full video episode on YouTube. Thank you so much for making Game On Glio a top 10 podcast nationally! Welcome to Season 5.   Season Sponsors: GammaTile Therapy Imvax Inc.   Episode Sponsor: Plus Therapeutics

Dr. Iyad Alnahhas interviews Dr. Peter LaViolette about his and his team's recent manuscript entitled: "Multi-Site Retrospective Analysis of Diffusion and Perfusion MRI Correlates to Glioma Characteristics Derived from Radio-Pathomic Maps", published online in Neuro-Oncology in February 2025.

Send us a textDr. Ashley Aaroe joins us today to talk all about Neuro-oncology, from brain tumor classification, to complications of chemotherapy and immunotherapy, to the importance of patient advocacy.Find her on X/Twitter.  Check out our website at www.theneurotransmitters.com to sign up for emails, classes, and quizzes! Would you like to be a guest or suggest a topic? Email us at contact@theneurotransmitters.com Follow our podcast channel on

Description: Dr. Evan Noch interviews Drs. Cecile Riviere-Cazaux and Terry Burns about their recent manuscript entitled: "A field resource for the glioma cerebrospinal fluid proteome: impacts of resection and location on biomarker discovery", published online in Neuro-Oncology in December 2024.   Link: https://doi.org/10.1093/neuonc/noae277  

Israel Gasperin is a visionary entrepreneur, engineering scientist and the founder of Zentrela, a company dedicated to transforming cannabis research through advanced neurotechnology and AI. Under Israel's leadership, Zentrela developed the Psychoactive Effect Level (PEL) metric, an innovative EEG-based measure capable of objectively assessing cannabis products' psychoactive potency. By combining wearable EEG technology with AI-driven EEG analysis, the PEL metric provides cannabis producers, researchers, and regulators with a non-invasive and cost-effective way to quantify product effects and maintain quality control.  At CannMed 25, Israel will share results from over 10,000 EEG scans of consumers using a wide range of cannabis products in his oral presentation titled “Cannabis Effect Research Driven by EEG Technology and Machine Learning”. During our conversation, we discuss:  How Zentrela's wearable EEG technology got its start measuring drowsiness in truck drivers   The unreliability of consumer feedback with regards to cannabis product effects  How the PEL metric was created to measure the unique psychoactive effects of cannabis How producers can use PEL to objectively measure the quality and effectiveness of cannabis products beyond cannabinoid percentages  Research findings that show THC% and PEL% are not directly correlated  and more  Thanks to This Episode's Sponsor: The DENT Institute With more than 300,000 patient visits per year, the DENT Neurologic Institute ranks among the largest neuroscience centers in North America. Its 24 subspecialty clinics often treat the most challenging neurologic conditions including but not limited to Migraine, Chronic pain, ALS, MS, Parkinson's, Dementia, and Neuro-Oncology. With their mission of advancing neuroscience, the Dent Institute established a cannabis clinic in 2016 to aid in the treatment of these chronic conditions seen throughout the institute. Learn more at dentinstitute.com Additional Resources Zentrela Website Israel Gasperin on LinkedIn Use of a Novel EEG-Based Objective Test, the Cognalyzer®, in Quantifying the Strength and Determining the Action Time of Cannabis Psychoactive Effects and Factors that May Influence Them Within an Observational Study Framework Sensitivity, Specificity and Accuracy of a Novel EEG-Based Objective Test, the Cognalyzer®, in Detecting Cannabis Psychoactive Effects Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters Review the Podcast CannMed Archive

Description: Dr. Ankush Bhatia interviews Drs. Macarena de la Fuente and Mehdi Touat about their recent manuscript entitled: "The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma" published online in Neuro-Oncology in December 2024.   Link: https://doi.org/10.1093/neuonc/noae259

Dr. Iyad Alnahhas interviews Dr. Craig Horbinski about his and his team's recent manuscript entitled "The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma", published online in Neuro-Oncology in December 2024.

Send us a textIn this episode we welcome Dr. Na Tosha Gatson, Director of Neuro-Oncology & Professor of Neurology and Medicine at IU Health. A leader in the field, Dr. Gatson shares insights on advancements in neuro-oncology, the impact of brain tumors on women's health, addressing health disparities, and the importance of quality-of-life care. Support the show

Drs Camidge and Boire discuss Dr Boire's journey to becoming a physician-scientist, moments in her career that shaped her fascination with neurology, and how studying human biology at the cellular level can ultimately help improve the lives of patients with cancer.